Cision PR Newswire

AccidentAccidentAir PollutionAll NewsAnnoucementArgricultureArtASEANBook

HONGQI EHS4 Set for Global Debut in Venice: Eastern Elegance Arrives in Europe

VENICE, Italy, Nov. 15, 2026 /PRNewswire/ -- HONGQI, one of China's leading automotive marques, will introduce its all-new all-electric SUV, HONGQI EHS4, to the European market. Making its global debut in Venice, Italy, on 16 November 2026, the EHS4 marks another milestone in the brand's international expansion. ...

EFICYENT to Join Banks and Fintech Companies at Singapore FinTech Festival 2026

Cision PR Newswire

SmallRig Joins Art World Figures to Discuss Creativity and Authenticity in the AI Era–and How Art and Technology Can Drive Innovation

SHENZHEN, China, Nov. 14, 2026 /PRNewswire/ -- As generative AI changes how images are...
Cision PR Newswire

PASCAL Unveils Its 2026 Holiday Gift Edit, Featuring Timeless Watches and Color-Driven Gifts

Launching November 14, the seasonal event centers on the Timeless Classic Collection, coordinated gifting...
Cision PR Newswire

AJOVY® Formally Included in China’s National Reimbursement Drug List 2026

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- On November 14, NeuroGen announced that it's in-licensed innovative...
Cision PR Newswire

Amorepacific Showcases Innovative Technologies at CES 2026

Award-Winning...

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG...

GMA Capital Partners Joins Responsible Investment Association Australasia

SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- GMA Capital Partners has been approved as a member of the Responsible Investment Association Australasia (RIAA), reflecting the...

C&R Research, the ‘K-Clinical Hub’, Strengthens Partnerships in Indonesia

Accelerating Indonesia Collaboration through Global Clinical Capabilities SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- C&R Research, founded in 1997 as Korea's first...

Hyundai Motor Group Executive Chair Chung Presents 2026 Vision: Customer-Focused Transformation and AI-Driven Ecosystem Collaboration

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30...
1...1,5941,5951,596...4,531Page 1,595 of 4,531